Manish Kothari was previously a director of commercial ventures and licensing at the corporate venturing unit, after initially joining SRI in 2013.

Neurology drug developer Ovid Therapeutics will use the Sanofi-backed series B round to fund the advancement of its lead candidate into Phase 2 trials.

Biotechnology company FortuneRock is set to float on the National Equities Exchange and Quotations in China, giving Jinhua Pharmaceuticals an exit.

Dave Schulte will join McKesson's corporate venturing fund next month, after 13 years at another CVC unit, Kaiser Permanente Ventures.

Google Ventures was among the broad range of backers in the genome editing company's series B round, bringing its total funding to more than $160m.

Technical University of Dresden has spun out a new company which identifies diseases through a high-speed camera.

Boehringer Ingelheim and Portage Biotech have provided series A funding to support a Phase 1 clinical trial for the treatment Sentien is developing for acute kidney injury.

MorphoSys, which owned a 20% stake following Lanthio's 2012 series A round, paid $22.5m for the remainder of the drug developer's shares.